Article
FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors.
The pharmacogenomics journal - 1 Jun 2017
Mendrinou E, Patsatsi A, Zafiriou E, Papadopoulou D, Aggelou L, Sarri C, Mamuris Z, Kyriakou A, Sotiriadis D, Roussaki-Schulze A, Sarafidou T, Vasilopoulos Y
Abstract excerpt
Psoriasis is a multifactorial skin disease affecting ~2% of world's population, causing a dramatic decrease in patients' quality of life and a significant increase in health-care expenses. Biological agents such as the anti-TNFα ones had an enormous impact in patients' therapy; however, a significant proportion of them do not respond well, an outcome attributed mainly to genetic factors. Recently, in a large...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.